Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price

RPRXStock

$62.07+68.86%52W

Market Cap$35.87B

P/E43.46x

PEG Ratio2.19

Div yield2.96%

Beta0.41

RPRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)24.02%

Price vs S&P 500 (4W)-0.78%

PEG Ratio2.19

VGM Score49.07

P/E Ratio (Annual)43.46x

Indicated Dividend Yield (Annual)2.96%

P/CF (Annual)13.46x

Book Value / Share (Quarterly)$11.87

P/TBV (Annual)4.26x

Indicated Dividend (Annual)$0.94

Revenue Growth (3Y)2.06%

Cash Flow / Share (Quarterly)$1.00

Payout Ratio (TTM)48.96%

Price vs S&P 500 (YTD)46.76%

Net Profit Margin (TTM)32.14%

EPS (TTM)$1.46

10-Day Avg Trading Volume2.59M

EPS Excl Extra (TTM)$1.46

Revenue Growth (5Y)2.30%

EPS (Annual)$1.37

Dividend / Share (Annual)$0.65

ROI (Annual)5.00%

Net Profit Margin (5Y Avg)29.51%

Cash / Share (Quarterly)$1.45

P/E Basic Excl Extra (TTM)41.11x

Revenue Growth QoQ (YoY)16.50%

EPS Growth (5Y)-12.06%

P/E Normalized (Annual)43.46x

ROA (Last FY)3.93%

Revenue Growth TTM (YoY)10.01%

EBITD / Share (TTM)$2.71

ROE (5Y Avg)10.63%

Operating Margin (TTM)59.61%

Cash Flow / Share (Annual)$1.37

P/B Ratio4.90x

P/B Ratio (Quarterly)4.73x

Net Income / Employee (Annual)$7,709,500

EV / Revenue (TTM)16.43x

Net Interest Coverage (TTM)6.99x

ROA (TTM)4.15%

EPS Growth QoQ (YoY)-40.22%

EV / EBITDA (TTM)27.56x

EPS Incl Extra (Annual)$1.37

Current Ratio (Annual)2.40x

Quick Ratio (Quarterly)2.80x

3-Month Avg Trading Volume3.45M

52-Week Price Return68.86%

EV / Free Cash Flow (Annual)52.59x

P/E Incl Extra (TTM)41.11x

Revenue / Employee (TTM)$25,360,000

Tangible BV / Share (Quarterly)$12.70

P/S Ratio (Annual)14.09x

Asset Turnover (Annual)0.12x

52-Week High$62.13

Operating Margin (5Y Avg)52.45%

EPS Excl Extra (Annual)$1.37

CapEx CAGR (5Y)-4.90%

26-Week Price Return35.27%

Quick Ratio (Annual)2.40x

13-Week Price Return14.53%

Total Debt / Equity (Annual)1.38x

Current Ratio (Quarterly)2.80x

Enterprise Value$41.66B

Revenue / Share Growth (5Y)-5.71%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)-2.00%

Revenue / Employee (Annual)$23,781,900

Pretax Margin (Annual)55.68%

Cash / Share (Annual)$1.10

3-Month Return Std Dev25.25%

Net Income / Employee (TTM)$8,150,000

EBITDA CAGR (5Y)-0.36%

EBITDA Interim CAGR (5Y)-29.24%

ROE (Last FY)11.90%

Net Interest Coverage (Annual)6.42x

EPS Basic Excl Extra (Annual)$1.37

P/FCF (TTM)40.04x

Receivables Turnover (TTM)150.73x

EV / Free Cash Flow (TTM)72.13x

Total Debt / Equity (Quarterly)1.31x

EPS Incl Extra (TTM)$1.46

Receivables Turnover (Annual)150.73x

ROI (TTM)5.22%

P/S Ratio (TTM)13.21x

Pretax Margin (5Y Avg)50.23%

Revenue / Share (Annual)$4.21

Tangible BV / Share (Annual)$12.70

Forward P/E10.85x

Price vs S&P 500 (52W)50.55%

P/E Ratio (TTM)41.11x

EPS Growth TTM (YoY)-15.92%

Year-to-Date Return58.72%

5-Day Price Return2.75%

EPS Normalized (Annual)$1.37

ROA (5Y Avg)3.87%

Net Profit Margin (Annual)32.42%

Month-to-Date Return4.96%

Cash Flow / Share (TTM)$0.66

EBITD / Share (Annual)$2.76

EPS Growth (3Y)140.90%

Operating Margin (Annual)65.58%

LT Debt / Equity (Annual)1.32x

P/CF (TTM)11.26x

ROI (5Y Avg)5.00%

P/E Excl Extra (TTM)41.11x

LT Debt / Equity (Quarterly)1.26x

EPS Basic Excl Extra (TTM)$1.46

P/TBV (Quarterly)4.26x

Payout Ratio (Annual)49.06%

P/B Ratio (Annual)3.44x

Dividend / Share (TTM)$0.69

Pretax Margin (TTM)53.23%

Book Value / Share (Annual)$11.22

Price vs S&P 500 (13W)11.73%

Net Margin Growth (5Y)-6.73%

Dividend Yield (TTM)1.19%

Beta0.41x

P/FCF (Annual)42.30x

Revenue / Share (TTM)$4.55

ROE (TTM)12.25%

52-Week Low$34.08

vGradeD

gGradeD

mGradeB

vgmGradeC

RPRX Earnings Surprise History

Q2 251.14est. 1.03

Q3 251.17est. 1.04

Q4 251.47est. 1.33

Q1 261.30est. 1.18

Q2 261.32est. 1.27

RPRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.19

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties, generating recurring revenue from fixed payments tied to the sales of commercial medications. The company receives royalties from a diversified portfolio of 35+ approved products across oncology, neurology, and rare genetic diseases, plus 10 development-stage candidates from major pharmaceutical companies including AbbVie, Johnson & Johnson, Biogen, and Vertex. This business model provides predictable cash flows from established market-leading drugs without the operational risks of drug development or commercialization.